CN104034898A - Kit for quantitatively detecting CEA (Carcino Embryonie Antigen) - Google Patents
Kit for quantitatively detecting CEA (Carcino Embryonie Antigen) Download PDFInfo
- Publication number
- CN104034898A CN104034898A CN201410279286.1A CN201410279286A CN104034898A CN 104034898 A CN104034898 A CN 104034898A CN 201410279286 A CN201410279286 A CN 201410279286A CN 104034898 A CN104034898 A CN 104034898A
- Authority
- CN
- China
- Prior art keywords
- kit
- cea
- container
- solution
- magnetic bead
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to a kit for quantitatively detecting CEA (Carcino Embryonie Antigen), and belongs to the immunodetection field. The kit for quantitatively detecting the CEA has high sensitivity, good specificity, simplicity in operation and short time spent on obtaining a detection result. The kit comprises a reagent-CEA magnetic separation reagent, an enzyme labeled antibody, an enhancer, a calibrator, a control product, a concentrated solution and a substrate. The kit adopts the combination of an immune magnetic particle isolation technology and a competitive enzyme linked immunosorbent assay technology, and compared with the prior art, the kit can greatly shorten the detection time.
Description
Technical field
The invention belongs to field of immunodetection, be specifically related to a kind of kit of quantitative detection CEA carcinomebryonic antigen.
Background technology
Carcinomebryonic antigen is the acidoglycoprotein that a kind of molecular weight is about 22KD.The encoding gene of CEA is positioned at chromosome No. 19, is the carcinogenic antigen of Embryo.CEA is mainly present in Fetus Digestive epithelial tissue, pancreas and liver, and in normal adult serum, content is extremely low, and the cancer cells secrete CEA that loses polarity enters blood and lymph, causes CEA level in blood to increase.CEA is mainly present in the tissues such as colon cancer, cancer of pancreas, cancer of the stomach, liver cancer, but when suffering from lung cancer, breast cancer, also has raising in various degree.
CEA is extensively present in the Alimentary System of endoderm origin, as cancer of the stomach, colorectal cancer, liver cancer, cancer of pancreas, also can be present in small-cell carcinoma of the lung, breast cancer, medullary carcinoma of thyroid gland.Therefore, detect CEA content in serum the diagnosis of above-mentioned cancer is had to auxiliary value.The clinical meaning of CEA is:
(1) for the clinical monitoring of colorectal cancer, cancer of the stomach, pancreas cancer, hepatocellular carcinoma, lung cancer, breast cancer and thyroid gland medullary substance cancer.
A. in pancreatic juice and bile, CEA quantitatively can be for Diagnosis of Pancreatic or cancer of bile ducts.
B. the CEA of serosity transudate quantitatively can be used as the supplementary means of cytolgical examination.
C. the CEA of urine quantitatively can be used as the reference of diagnosing bladder cancer prognosis.
D. quantitatively the measuring in conjunction with thyrocalcitonin of CEA in serum, contributes to the diagnosis of medullary carcinoma of thyroid gland and the estimation of recurrence.
(2) for predicting the prognosis of malignant tumour: early, result for the treatment of is good for the lower explanation course of disease of CEA concentration, and the time-to-live is long.
(3) can detect curative effect: after treatment, serum levels will drop to normal level, as recurred or treating unsuccessfully by twice rising.
(4) can follow the tracks of recurrence: after treatment, CEA raises again again, prompting has transfer possibility.
Summary of the invention
The technical issues that need to address of the present invention are to provide a kind of quantitative detection CEA carcinomebryonic antigen kit and detection method thereof,
Adopt this kit to carry out the detection of CEA carcinomebryonic antigen and there is higher sensitivity and specificity, and the time of shorter acquisition testing result and easier mode of operation.
Kit provided by the invention, its reagent comprising has CEA carcinomebryonic antigen magnetic separation agent, enzyme labelled antibody, reinforcing agent, calibration object, control product, concentrate and substrate.
Described magnetic separation agent contains the magnetic microsphere that is marked with Cea Monoclonal Antibodies.
Described enzyme labelled antibody is the Cea Monoclonal Antibodies that contains horseradish peroxidase-labeled.
Described reinforcing agent is the damping fluid that contains Tris.
Described calibration object and control product are the solution that contains a certain amount of carcinomebryonic antigen antigen.
Described concentrate is the damping fluid that contains TWEEN-20 and Proclin-300.
Described substrate is enzyme-catalyzed chemical luminescence substrate.
The immue quantitative detection reagent box of CEA carcinomebryonic antigen of the present invention, is preferably prepared from as follows:
The first step: the preparation process of magnetic separation agent:
1,1.0mg disuccinimidyl suberate is dissolved in 50ul DMSO, get in the 0.1mol/L PB damping fluid that 2mg Cea Monoclonal Antibodies is dissolved in PH 9.5 to cumulative volume be 1ml;
2, with the disuccinimidyl suberate that liquid-transfering gun is drawn in step 1, join in the antibody-solutions of step 1, put room temperature 90min;
3, step 2 antibody-solutions is joined in concentration tube, then put in high speed freezing centrifuge under 3000g concentrated 30min to volume be 0.5ml;
4, get 0.5ml magnetic bead, add in 5ml reaction cup, put into test tube rack special, through magnet adsorption, after 2 minutes, draw supernatant;
5, add 1.5ml PH9.50.1mol/L PB at every turn, mix 30 seconds, added, remove supernatant, repetitive operation 3 times; To walk
Rapid 3 antibody-solutions that obtain join in above-mentioned magnetic bead, mix rear room temperature reaction 4 hours;
6,37 ℃ of the TRIS solution 15 minutes that add 0.3ml 1mol/L;
7, add 1.5ml PH 7.20.1mol/L PB to clean the magnetic bead of mark at every turn, mix 30 seconds, added, remove supernatant,
Repetitive operation 3 times;
8, with 100ml magnetic bead, preserve liquid magnetic bead is proceeded to 125ml vial; It is (being mass volume ratio) that magnetic bead is preserved formula of liquid
0.1%BSA, 0.05% Tween-20,0.02%NaN3,20% ethanol, 4 ℃ of preservations.
9, by magnetic bead buffer solution, the volume ratio according to 1: 1 mixes magnetic separation agent step 8 being obtained, and obtains kit of the present invention
Middle magnetic separation agent; Described magnetic bead buffer solution is that concentration is the TRIS-HCl damping fluid of 1mol/L.
Second step: enzyme labelled antibody preparation process:
1,2.5mg Cea Monoclonal Antibodies is dissolved in the N of 1.0ml, in dinethylformamide, add 10mg/ml horseradish peroxidase aqueous solution and the 1.3mg carbodiimides of 1ml, after 1 hour, the carbodiimides of 1.0ml 20mg/ml is added, potpourri constantly stirs, and 4 ℃ are spent the night;
2, the solution of step 1 is packed in bag filter, to the PH7.4PBS dialysis of 0.15M, 4 ℃ are spent the night, and collect and retain liquid;
Then adding 10ml concentration is the BSA solution of 15mg/ml, and 4 ℃ store for future use; Finally by the conjugate of the horseradish peroxidase of collecting and Cea Monoclonal Antibodies, with enzyme labelled antibody dilution, the volume ratio with 1: 1000 mixes, and obtains enzyme labelled antibody; Described enzyme labelled antibody dilution is that concentration is the TRIS-HCl damping fluid of 1mol/L.
The 3rd step: reinforcing agent preparation steps:
1, take TRIS1.56g and NaCl 4.23g in 1L container; With pipettor, Proclin-300 is measured to 0.2ml in 10ml
After dissolving completely in the beaker of purified water, pour in above-mentioned 1L container;
2, with graduated cylinder, measure 800ml purified water in above-mentioned 1L container, fully stir, until dissolve completely, adjust PH, control PH between 7.35-7.45;
3, take Mak330.9g in above-mentioned 1L container; Last constant volume 1000ml, after dissolving completely, filters with 0.2um filter.
The 4th step: the preparation of calibration object and the product of control:
Calibration object concentration is respectively 0,2,5,10,20,50,100,200, the ng/ml of unit; Control product concentration is respectively 0.20,0.80ng/ml.
The 5th step:
Concentrate preparation steps, preparation 1L:
1, take TRIS 12.54g and NaCl 325.6g in 1L container;
2, after taking 5g Tween-20 and adding 20ml water in 100ml container it is dissolved completely, pour in above-mentioned 1L container;
3, with pipettor, Proclin-300 is measured after 0.2ml dissolves completely in the beaker that fills 10ml purified water, pour into above-mentioned
In 1L container;
4, with graduated cylinder, measure 800ml purified water in above-mentioned 1L container, fully stir, until dissolve completely;
5, adjust PH, control its scope between 7.35-7.45;
6, last constant volume 1000ml, filters and get final product with 0.2um filter after dissolving completely.
The 6th step: substrate preparation steps, preparation 1L:
1, take TRIS 2.35g, NaCl 6.41g, Na2SO30.002g and Proclin-3000.2ml in 1L beaker;
2, with graduated cylinder, measure 600ml purified water in 1L beaker, fully stir, until dissolve completely, adjust PH, control its scope between 7.95-8.05;
3, add after 250ml Lumi-Phos 530, with 0.2um filter, filter and collect filtrate, by purified water, be settled to 1000ml,
After mixing and get final product.
Main innovation part of the present invention is:
1, kit of the present invention combines chemiluminescence with immune magnetic particle, and a kind of reaction system that approaches homogeneous phase is provided,
Compared with prior art, kit of the present invention has higher detection sensitivity and specificity, and has reached preferably performance parameter.
2, the invention discloses a kind of new special-purpose reinforcing agent and concentrate, make course of reaction more reliable and more stable, experiment number
According to sensitive, effectively can be accurate to 0.01ng, when enhancing product performance, and greatly reduce cost of products;
3, the carcinomebryonic antigen magnetic separation agent in this kit, enzyme labelled antibody, reinforcing agent, calibration object, control product, concentrate with
And substrate is all the optimization formulas under this reaction system, giving the use effect phase of this kit and detecting performance provides powerful guarantee.
Embodiment
Embodiment 1,
One, carcinomebryonic antigen magnetic separation agent preparation process:
1,1.0mg disuccinimidyl suberate is dissolved in 50ul DMSO, get in the 0.1mol/L PB damping fluid that 2mg Cea Monoclonal Antibodies (Santa Cruz company product) is dissolved in PH 9.5 to cumulative volume be 1ml;
2, with the disuccinimidyl suberate that liquid-transfering gun is drawn in step 1, join in the antibody-solutions of step 1, put room temperature 90min;
3, the solution of step 2 is joined and in Centricon-10 concentration tube, then put in high speed freezing centrifuge under 3000g
Concentrated 30min to volume be 0.5ml;
4, get 0.5ml magnetic bead, add in 5ml reaction cup, put into test tube rack special, through magnet adsorption, after 2 minutes, draw supernatant;
Magnetic bead is the conventional magnetic bead in this area, preferred concentration 25mg/mL, and diameter is 800nm.
5, add 1.5ml PH9.50.1mol/L PB at every turn, mix 30 seconds, added, remove supernatant, repetitive operation 3 times; To walk
Rapid 4 antibody-solutions that obtain join in above-mentioned magnetic bead, mix rear room temperature reaction 4 hours;
6,37 ℃ of the TRIS solution 15 minutes that add 0.3ml 1mol/L;
7, add 1.5ml PH 7.20.1mol/L PB to clean the magnetic bead of mark at every turn, mix 30 seconds, added, remove supernatant,
Repetitive operation 3 times;
8, with 100ml magnetic bead, preserve liquid magnetic bead is proceeded to 125ml vial; It is 0.1%BSA that magnetic bead is preserved formula of liquid, and 0.05% tells
Temperature-20,0.02%NaN3,20% ethanol (being mass volume ratio), 4 ℃ of preservations.
9, by magnetic bead buffer solution, the volume ratio according to 1: 1 mixes magnetic separation agent step 8 being obtained, and obtains kit of the present invention
Middle magnetic separation agent; Described magnetic bead buffer solution is that concentration is the TRIS-HCl damping fluid of 1mol/L.
Embodiment 2
One, the preparation process of enzyme labelled antibody:
1,2.5mg Cea Monoclonal Antibodies is dissolved in the N of 1.0ml, in dinethylformamide, add 10mg/ml horseradish peroxidase aqueous solution and the 1.3mg carbodiimides of 1ml, after 1 hour, the carbodiimides of 1.0ml 20mg/ml is added, potpourri constantly stirs, and 4 ℃ are spent the night;
2, the solution of step 1 is packed in bag filter, to the PH7.4PBS dialysis of 0.15M, 4 ℃ are spent the night, and collect and retain liquid;
Then adding 10ml concentration is the BSA solution of 15mg/ml, and 4 ℃ store for future use; Finally by the conjugate of the horseradish peroxidase of collecting and Cea Monoclonal Antibodies, with enzyme labelled antibody dilution, the volume ratio with 1: 1000 mixes, and obtains enzyme labelled antibody; Described enzyme labelled antibody dilution is that concentration is the TRIS-HCl damping fluid of 1mol/L.
Embodiment 3
Reinforcing agent preparation steps:
1, take TRIS1.56g and NaCl 4.23g in 1L container; With pipettor, Proclin-300 is measured to 0.2ml in 10ml
After dissolving completely in the beaker of purified water, pour in above-mentioned 1L container;
2, with graduated cylinder, measure 800ml purified water in above-mentioned 1L container, fully stir, until dissolve completely, adjust PH, control PH between 7.35-7.45;
3, take Mak33 0.9g in above-mentioned 1L container; Last constant volume 1000ml, after dissolving completely, filters with 0.2um filter.
Mak33 is the commercial reagent of Roche Holding Ag.
Embodiment 4
The preparation steps of calibration object and the product of control:
1, by purified water, to be mixed with concentration point be 0,2,5,10,20,50,100,200 to carcinomebryonic antigen immue quantitative detection reagent box carcinomebryonic antigen calibration object raw material (being purchased from Santa Cruz company), the ng/ml of unit; Control product with the concentration point of purified water preparation be 0.20,0.80ng/ml.
2, after dissolving completely, post label in 2-8 ℃ of refrigeration house storage, the term of validity is 12 months.
Embodiment 5:
Concentrate preparation steps:
1, take carcinomebryonic antigen 12.54g and NaCl 325.6g in 1L container;
2, after taking 5g Tween-20 and adding suitable quantity of water in 100ml container it is dissolved completely, pour in said vesse;
3, with pipettor, Proclin-300 is measured after 0.2ml dissolves completely in the beaker that fills 10ml purified water, pour into above-mentioned
In 1L container;
4, with graduated cylinder, measure 800ml purified water in above-mentioned 1L container, fully stir, until dissolve completely;
5, with HCL or NaOH, adjust PH, measure its scope between 7.35-7.45;
6, last constant volume 1000ml, surveys pH value, and scope meets the requirements between 7.35-7.45, after dissolving completely, with 0.2um, filters
Device filters; After having filtered, post label in 2-8 ℃ of refrigeration house storage, the term of validity is 12 months;
Embodiment 6
Substrate formulation operations step:
1, take TRIS 2.35g, NaCl 6.41g, Na
2sO
30.002g and Proclin-300 0.2ml are in 1L beaker;
2, with graduated cylinder, measure 600ml purified water in 1L beaker, fully stir, until dissolve completely; With HCl or NaOH, adjust PH, measure its scope between 7.95-8.05;
3, add after 250ml Lumi-Phos 530, with 0.2um filter, filter and collect filtrate, by purified water, be settled to 1000ml,
After mixing, post label in 2-8 ℃ of refrigeration house storage, the term of validity is 12 months.
The using method of kit of the present invention is as follows:
1, add 15 μ l carcinomebryonic antigen calibration objects, quality-control product, sample to be measured to corresponding test tube bottom.
2, add 25 μ l enzyme labelled antibodies to each test tube.
3, add 25 μ l reinforcing agents to each test tube.
4, add 25 μ l magnetic separation agents to each test tube.
5, multitube vortex mixer vibrates gently and is placed with after the test tube rack 30s of test tube, puts 37 ℃ of water-baths 30 minutes.
6, test tube frame linking is put to magnetic separator, guarantees that every test tube all contacts with separator surface, precipitates 2 minutes, and the separation vessel that then reverses is slowly poured out supernatant.
7, concentrate is with after 10 times of purified water dilutions, adds concentrate after 100 μ l dilutions to each test tube, puts on multitube vortex mixer vibration gently and mixes 30s.
8, add 100 μ l substrate solutions and mix 3 seconds to test tube, with ready luminous detector, detect rapidly.
Claims (3)
1. quantitatively detect a CEA carcinomebryonic antigen kit, it is characterized in that, this kit comprises CEA carcinomebryonic antigen magnetic separation agent, enzyme labelled antibody, reinforcing agent, calibration object, control product, concentrate and substrate.
2. kit as claimed in claim 1, is characterized in that, described magnetic separation agent contains the magnetic microsphere that is marked with Cea Monoclonal Antibodies; Described enzyme labelled antibody is the Cea Monoclonal Antibodies that contains horseradish peroxidase-labeled.
Described reinforcing agent is the damping fluid that contains Tris; Described calibration object and control product are the solution that contains a certain amount of carcinomebryonic antigen antigen; Described concentrate is the damping fluid that contains TWEEN-20 and Proclin-300; Described substrate is enzyme-catalyzed chemical luminescence substrate.
3. the preparation method of kit as claimed in claim 1:
The first step: the preparation process of CEA carcinomebryonic antigen magnetic separation agent:
1) 1.0mg disuccinimidyl suberate is dissolved in 50ul DMSO, get in the 0.1mol/L PB damping fluid that 2mg Cea Monoclonal Antibodies is dissolved in PH9.5 to cumulative volume be 1ml;
2) with the disuccinimidyl suberate that liquid-transfering gun is drawn in step 1, join in the antibody-solutions of step 1, put room temperature 90min;
3) solution step 2 being obtained join in concentration tube, then put in high speed freezing centrifuge under 3000g concentrated 30min to volume be 0.5ml;
4) get 0.5ml magnetic bead, add in 5ml reaction cup, put into test tube rack, through magnet adsorption, after 2 minutes, draw supernatant;
5) antibody-solutions that adds step 3 to obtain, mixes rear room temperature reaction 4 hours;
6) add 37 ℃ of the TRIS solution 15 minutes of 0.3ml 1mol/L;
7) add 1.5ml PH7.20.1mol/LPB to clean the magnetic bead of mark, mix 30 seconds, added, remove supernatant;
8) with 100ml magnetic bead, preserve liquid magnetic bead is proceeded to 125ml vial; It is 0.1%BSA that magnetic bead is preserved formula of liquid, 0.05% Tween-20,0.02%NaN3,20% ethanol, 4 ℃ of preservations;
9) by magnetic bead buffer solution, the volume ratio according to 1: 1 mixes solution step 8 being obtained, and obtains magnetic separation agent in kit; Described magnetic bead buffer solution is that concentration is the TRIS-HCl damping fluid of 1mol/L;
Second step: enzyme labelled antibody preparation process:
1) 2.5mg Cea Monoclonal Antibodies is dissolved in the N of 1.0ml, in dinethylformamide, add 10mg/ml horseradish peroxidase aqueous solution and the 1.3mg carbodiimides of 1ml, after 1 hour, the carbodiimides of 1.0ml20mg/ml is added, potpourri constantly stirs, and 4 ℃ are spent the night;
2) solution of step 1 is packed in bag filter, to the PH7.4PBS dialysis of 0.15M, 4 ℃ are spent the night, and collect and retain liquid; Then adding 10ml concentration is the BSA solution of 15mg/ml, and 4 ℃ store for future use; Finally by above-mentioned solution, with enzyme labelled antibody dilution, the volume ratio with 1: 1000 mixes, and obtains enzyme labelled antibody; Described enzyme labelled antibody dilution is that concentration is the TRIS-HCl damping fluid of 1mol/L;
The 3rd step: reinforcing agent preparation steps:
1) take TRIS1.56g and NaC14.23g in 1L container; With pipettor, Proclin-300 is measured after 0.2ml dissolves completely in the beaker of 10ml purified water, pour in above-mentioned 1L container;
2) with graduated cylinder, measure 800ml purified water in above-mentioned 1L container, fully stir, until dissolve completely, adjust PH between 7.35-7.45;
3) take Mak330.9g in above-mentioned 1L container; Last constant volume 1000ml, after dissolving completely, filters with 0.2um filter; The 4th step: the preparation of calibration object and the product of control:
Carcinomebryonic antigen compound concentration is respectively to 0,2,5,10,20,50,100,200, the calibration object of the ng/ml of unit; Carcinomebryonic antigen is mixed with to concentration is respectively 0.20, the control product of 0.80ng/ml;
The 5th step:
Concentrate preparation steps, preparation 1L:
1) take carcinomebryonic antigen 12.54g and NaCl325.6g in 1L container;
2) after taking 5g Tween-20 and adding 20ml water in 100ml container it is dissolved completely, pour in above-mentioned 1L container;
3) with pipettor, Proclin-300 is measured after 0.2ml dissolves completely in the beaker that fills 10ml purified water, pour in above-mentioned 1L container;
4) with graduated cylinder, measure 800ml purified water in above-mentioned 1L container, fully stir, until dissolve completely;
5) adjust PH, control its scope between 7.35-7.45;
6) last constant volume 1000ml, filters and get final product with 0.2um filter after dissolving completely;
The 6th step: substrate preparation steps, preparation 1L:
1) take TRIS2.35g, NaC16.41g, Na2SO30.002g and Proclin-3000.2ml in 1L beaker;
2) with graduated cylinder, measure 600ml purified water in 1L beaker, fully stir, until dissolve completely, adjust PH between 7.95-8.05;
3) add after 250ml Lumi-Phos530, with 0.2um filter, filter and collect filtrate, by purified water, be settled to 1000ml, after mixing and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410279286.1A CN104034898A (en) | 2014-06-21 | 2014-06-21 | Kit for quantitatively detecting CEA (Carcino Embryonie Antigen) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410279286.1A CN104034898A (en) | 2014-06-21 | 2014-06-21 | Kit for quantitatively detecting CEA (Carcino Embryonie Antigen) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104034898A true CN104034898A (en) | 2014-09-10 |
Family
ID=51465745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410279286.1A Withdrawn CN104034898A (en) | 2014-06-21 | 2014-06-21 | Kit for quantitatively detecting CEA (Carcino Embryonie Antigen) |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104034898A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105467137A (en) * | 2015-11-26 | 2016-04-06 | 北京豪迈生物工程有限公司 | Free human chorionic gonadotropin beta-subunit test kit and test method |
| CN105548549A (en) * | 2015-12-08 | 2016-05-04 | 孙丽华 | Kit for quantitative detection of carcinoembryonic antigen (CEA) and preparation method of kit |
| CN106526165A (en) * | 2016-11-08 | 2017-03-22 | 北京久峰润达生物技术有限公司 | Quantitative measurement kit for glypican and detection method thereof |
-
2014
- 2014-06-21 CN CN201410279286.1A patent/CN104034898A/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105467137A (en) * | 2015-11-26 | 2016-04-06 | 北京豪迈生物工程有限公司 | Free human chorionic gonadotropin beta-subunit test kit and test method |
| CN105548549A (en) * | 2015-12-08 | 2016-05-04 | 孙丽华 | Kit for quantitative detection of carcinoembryonic antigen (CEA) and preparation method of kit |
| CN106526165A (en) * | 2016-11-08 | 2017-03-22 | 北京久峰润达生物技术有限公司 | Quantitative measurement kit for glypican and detection method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108362688B (en) | Detection kit for chemiluminescence of 25-hydroxy vitamin D magnetic particles | |
| CN102507947B (en) | CEA TRFIA (time-resolved fluoroimmunoassay) kit based on IMB (immunomagnetic beads) | |
| CN103604931B (en) | A kind of people's S100 protein assay reagent and preparation method | |
| CN107543932A (en) | The magnetic microparticle chemiluminescence detection kit and preparation method of a kind of calcitonin | |
| CN103698535B (en) | Platelet-activating factor acetylhydro-lase immue quantitative detection reagent box and preparation, method of operating | |
| CN104122394A (en) | Quantitative determination kit and detection method for human epidermal growth factor receptor 2(Her-2) | |
| CN101395473A (en) | Water-soluble conjugates for electrochemical detection | |
| CN103364558A (en) | Human tumor marker carcinoembryonic antigen (CEA) magnetic particle chemiluminiscence immunoassay kit and detection method | |
| CN102495215B (en) | Kit for quantitatively detecting tumor necrosis factor alpha | |
| CN103499692B (en) | Golgiosome protein GP 73 quantitative determination reagent kit and detection method thereof | |
| CN103389375B (en) | A kind of liquid phase chip reagent box for pulmonary cancer diagnosis | |
| CN108603880A (en) | The detection method of tested substance and the detection kit of tested substance | |
| CN103575891A (en) | Kit for comprehensively detecting HE4 and CA125 and application of kit | |
| CN104034898A (en) | Kit for quantitatively detecting CEA (Carcino Embryonie Antigen) | |
| CN105510593A (en) | Thyroglobulin (TG) test kit and test method thereof | |
| CN110702926A (en) | Gastrin G17 detection kit and preparation method thereof | |
| CN102426255A (en) | Quantitative detection kit and detection method of free tetraiodothyronine (FT4) | |
| Fu et al. | A channel-resolved approach coupled with magnet-captured technique for multianalyte chemiluminescent immunoassay | |
| EP3614146A1 (en) | Method for detecting aldosterone and renin | |
| CN110082537A (en) | Vascular endothelial growth factor chemiluminescence immune detection reagent kit and preparation method thereof | |
| CN105467137A (en) | Free human chorionic gonadotropin beta-subunit test kit and test method | |
| CN103424551A (en) | Kit for performing quantitative detection on human epididymal epithelial secretory protein 4 and detection method thereof | |
| CN109142753A (en) | Squamous cell carcinoma-related antigen chemiluminescence immune detection reagent kit and preparation method thereof | |
| CN102426254B (en) | Total thyroxine (TT4) quantitative determination kit and its detection method | |
| JP5996234B2 (en) | Immunoassay method and reagent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20140910 |